BLTE Projected Dividend Yield

ADR/Belite Bio Inc ( NASDAQ : BLTE )

Belite Bio is a clinical stage biopharmaceutical drug development company focused on therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. Co.'s primary product candidate, LBS-008, or Tinlarebant is an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A (retinol) to the eye as a means to reduce the accumulation of toxic vitamin A by-products in ocular tissue.

20 YEAR PERFORMANCE RESULTS